Navigation Links
Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
Date:3/23/2010

SOUTH SAN FRANCISCO, Calif., March 23 /PRNewswire/ -- Portola Pharmaceuticals, Inc. today announced that it has initiated its first in human Phase 1 trial in healthy volunteers of PRT062607, a novel, oral Syk-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In preclinical in vivo models of RA, PRT062607 was shown to reduce inflammation in a dose-dependent manner.

PRT062607 is Portola's lead compound discovered from an extensive kinase chemistry effort that has led to the development of potent, oral inhibitors of Spleen Tyrosine Kinase (Syk) and Janus Kinase (JAK).  Syk and JAK play key roles in signaling pathways that modulate inflammation and certain cancers.  PRT062607 has been shown to be a highly specific inhibitor of Syk in a broad panel of in vitro kinase and cellular assays.

"Because of its key role as a mediator in a number of important signaling pathways, specific, low-level Syk inhibition may be ideal for the management of chronic inflammatory diseases, such as RA, and may be better tolerated than less selective kinase inhibitors," said Daniel D. Gretler, M.D., chief medical officer of Portola.  "The initiation of the Phase 1 trial of PRT062607 is an important milestone toward our goal of developing safe and efficacious oral drugs for rheumatoid arthritis and other chronic inflammatory diseases."

The ascending, single-dose Phase 1 study is assessing the safety, pharmacokinetics and pharmcodynamics of oral PRT062607 in up to 48 healthy individuals. The trial is being conducted at a single U.K. site.  It is expected to be completed in the second half of 2010.

Rheumatoid arthritis, a debilitating and degenerative autoimmune disease, affects approximately 1.3 million people, or about 0.6 percent of the U.S. adult population.(1) An inflammatory disease, it causes pain, swelling, stiffness and loss of function in the joints.  Current treatments include corticosteroids, nonsteroidal inflammatory drugs (NSAIDs), methotrexate and injectable biologic response modifiers.  Portola's product candidate, PRT062607, is orally available and could provide an alternative or supplement to currently used agents, if approved.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals develops innovative therapeutics based on targets with established proofs of concept that are designed to provide significant advances over current treatments for cardiovascular disease and inflammation. The company has global development and commercialization agreements with two of the world's leading pharmaceutical companies collectively valued at about $1 billion in upfront and milestone payments plus double-digit royalties on future sales. Betrixaban, its oral direct Factor Xa inhibitor, is licensed to Merck & Co., Inc., and elinogrel, its competitive, reversible P2Y(12) ADP receptor antagonist, is licensed to Novartis. Both are Phase 2 product candidates that have best-in-class features to address the global multi-billion dollar hospital, specialty and chronic care anticoagulant and antiplatelet markets, respectively.

Portola's proprietary pipeline programs are focused on the discovery and development of PRT061103, a thromboxane receptor antagonist, which is targeted to address a significant unmet need as a potential aspirin alternative for patients intolerant to aspirin; PRT064445, a Factor Xa inhibitor antidote to help manage or reverse the bleeding complications in the tens of millions of patients expected to be treated with Factor Xa inhibitors or low-molecular weight heparin worldwide in the next decade; and PRT062607, a novel, oral Syk-specific kinase inhibitor to treat chronic inflammatory diseases, including rheumatoid arthritis, and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. For additional information, visit www.portola.com.

(1) http://www.niams.nih.gov/Health_Info/Rheumatic_Disease/default.asp

SOURCE Portola Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.portola.com

'/>"/>

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
2. Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders
3. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
4. Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
5. Isis Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference
6. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
7. Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
8. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results
9. Poniard Pharmaceuticals Announces $6.3 Million Financing
10. MicuRx Pharmaceuticals Files Investigational New Drug Application for MRX-I
11. Adamas Pharmaceuticals TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and providing ... is in conjunction with this morning,s announcement of the ... and Nutritional Insufficiency businesses. Cardinal Health now ... will be at the bottom of its previous guidance ...
(Date:4/18/2017)... 18, 2017 Viverae ® , a leader ... integration of IBM ® Watson Campaign Automation, implementing ... communications for a personalized experience. Through digital engagement, the ... health in real time. The enhanced experience drives engagement ... members, wherever they are in their journey to health. ...
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., developer ... series to be presented at the 2017 National Kidney ... today and continues through April 22. Physicians will present ... used to assess risk for acute kidney injury (AKI) ... failure (ADHF). Elevated levels of TIMP-2 ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... The National Business Research ... National Registry of Emergency Medical Technicians and welcomes this organization to the ... Jan G. West, Ph.D. , CEO & Organizational Psychologist at NBRI. “This award ...
(Date:4/26/2017)... ... April 26, 2017 , ... RawTrition now brings you BioEnergy which ... nutrients from SUPERFOODS! , RawTrition is taking nutrients to the next level! ... the body recognizes its raw form (unlike the synthetically made options that are on ...
(Date:4/26/2017)... Doylestown, Pa. (PRWEB) , ... ... ... Solutions division, which provides an agile ecosystem and domain expertise for sponsors ... end-to-end, configurable randomization and trial supply management (RTSM) software platform. Bioclinica ...
(Date:4/25/2017)... ... April 25, 2017 , ... Splashtop ... Mirroring360 Pro . This new addition to the Mirroring360 product family combines device ... business. , Mirroring360 Pro enables educators, business professionals and individuals to stream or ...
(Date:4/25/2017)... ... April 25, 2017 , ... A stressful work environment can hurt the ... overall productivity and performance in the workplace. The goal of Clearview Resolution Services has ... weeks of April, Clearview Resolution Services will be shutting down the office early on ...
Breaking Medicine News(10 mins):